A Head-to-Head Comparison of Intralesional Furosemide-Digoxin Versus Polidocanol for the Treatment of Cutaneous Warts With 6-Month Follow-up
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Complete Clinical Response
研究概览
简要总结
This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.
详细描述
This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients over 18 years of age with single or multiple cutaneous warts.
排除标准
- •History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.
研究组 & 干预措施
Furosemide and digoxin
Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)
干预措施: Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) (Drug)
Polidocanol
Intralesional Polidocanol 2%
干预措施: Intralesional polidocanol 2% (Drug)
结局指标
主要结局
Complete Clinical Response
时间窗: Up to 8 weeks
100% clearance of the treated wart at the end of the treatment period.
次要结局
- Incidence and Severity of Adverse Effects(Throughout the treatment period (up to 8 weeks))
- Recurrence Rate(6 months post-treatment)
研究者
Ghada Mohamed Shams
Principal investigator
Benha University